OSE.PA

OSE Immunotherapeutics SA [OSE.PA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

OSE.PA Stock Summary

Earnings are expected to rise 3492.28% next year

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has been decreasing for the past 3 years (Yearly statements)

Debt-to-Equity ratio of 1.86 is considered moderate, deeper research suggested.

Top 10 Correlated Stocks

OSE.PA

In the News

OSE.PA Financial details

Company Rating

Neutral

Market Cap

102.24M

Income

-40.76M

Revenue

20.53M

Book val./share

Cash/share

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

22 Apr 2024

P/E

-4.92

Forward P/E

2.31

PEG

-0.4

P/S

40.78

P/B

3.5

P/C

P/FCF

-5.59

Quick Ratio

0.81

Current Ratio

1.49

Debt / Equity

1.86

LT Debt / Equity

1.55

EPS (TTM)

-2.15

EPS next Y

EPS next Q

EPS this Y

22.92%

EPS next Y

-193.03%

EPS next 5Y

-231.63%

EPS last 5Y

30.65%

Revenue last 5Y

-38.81%

Revenue Q/Q

-36.01%

EPS Q/Q

-15.63%

SMA20

-4.23%

SMA50

22.37%

SMA100

6.25%

Inst Own

Inst Trans

ROA

-20%

ROE

862%

ROC

-0.16%

Gross Margin

100%

Oper. Margin

-443%

Profit Margin

-711%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

2.705-7.31

52W High

-33.93%

52W Low

+131.25%

RSI

46.76

Rel Volume

0.07

Avg Volume

120.72K

Volume

8.89K

Perf Week

-4.84%

Perf Month

-7.5%

Perf Quarter

3.47%

Perf Half Y

0.76%

Beta

0.78

Volatility

0.06%, 0.18%

Prev Close

0.11%

Price

4.625

Change

-1.8%

OSE.PA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.74	0.67	1.45	0.99	0.11
Net income per share	-0.31	-1.06	-0.93	-0.96	-1.18
Operating cash flow per share	0.6	-1.26	-0.55	-0.99	-1.01
Free cash flow per share	0.58	-1.27	-0.57	-1	-1.02
Cash per share	1.74	1.89	1.85	1.39	0.95
Book value per share	3.93	3.94	2.62	1.76	1.17
Tangible book value per share	0.4	0.56	-0.2	-0.88	1.17
Share holders equity per share	3.93	3.94	2.62	1.76	1.17
Interest debt per share	0.69	1.12	1.87	2.31	2.31
Market cap	55.1M	112M	186.63M	123.2M	83.73M
Enterprise value	40.74M	102.15M	190.19M	142.38M	110.85M
P/E ratio	-11.84	-6.77	-11.08	-6.94	-3.64
Price to sales ratio	2.12	10.75	7.09	6.73	37.6
POCF ratio	6.14	-5.73	-18.82	-6.75	-4.24
PFCF ratio	6.38	-5.67	-17.96	-6.65	-4.19
P/B Ratio	0.94	1.83	3.93	3.79	3.64
PTB ratio	0.94	1.83	3.93	3.79	3.64
EV to sales	1.57	9.81	7.23	7.78	49.78
Enterprise value over EBITDA	-8.9	-4.26	-9.82	-6.95	-4.37
EV to operating cash flow	4.54	-5.23	-19.17	-7.8	-5.61
EV to free cash flow	4.72	-5.17	-18.3	-7.69	-5.54
Earnings yield	-0.08	-0.15	-0.09	-0.14	-0.27
Free cash flow yield	0.16	-0.18	-0.06	-0.15	-0.24
Debt to equity	0.17	0.28	0.7	1.27	1.86
Debt to assets	0.11	0.18	0.33	0.45	0.52
Net debt to EBITDA	3.14	0.41	-0.18	-0.94	-1.07
Current ratio	2.31	2.82	2.64	2.29	1.62
Interest coverage	-27.96	-90.61	-26.28	-17.52	-11.93
Income quality	-1.93	1.18	0.59	1.03	0.86
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.15	0.45	0.32	0.36	0
Research and developement to revenue	0.97	2.67	1.29	1.63	10.31
Intangibles to total assets	0.59	0.54	0.5	0.53	0
Capex to operating cash flow	-0.04	0.01	0.05	0.02	0.01
Capex to revenue	-0.01	-0.02	-0.02	-0.01	-0.1
Capex to depreciation	-0.7	-0.29	-0.18	-0.08	-0.07
Stock based compensation to revenue	0.07	0.22	0.14	0.15	0
Graham number	5.25	9.71	7.39	6.18	5.57
ROIC	-0.07	-0.21	-0.2	-0.24	-0.33
Return on tangible assets	-0.13	-0.37	-0.33	-0.41	-0.28
Graham Net	-0.03	-0.02	-0.81	-1.48	-2.03
Working capital	18.73M	25.7M	27.44M	20.93M	11.68M
Tangible asset value	5.89M	8.64M	-3.59M	-16.24M	22.98M
Net current asset value	2.66M	4.22M	-9.78M	-21.92M	-28.6M
Invested capital	0.17	0.28	0.7	1.27	1.86
Average receivables	3.84M	6.7M	7.82M	7.9M	4.56M
Average payables	5.42M	5.84M	5.17M	3.76M	6.93M
Average inventory	0	0	0	0	0
Days sales outstanding	76.41	279.16	106.33	162.1	160.95
Days payables outstanding	195.46K	-2.7M	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	4.78	1.31	3.43	2.25	2.27
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.08	-0.27	-0.35	-0.55	-1
Capex per share	-0.02	-0.01	-0.03	-0.01	-0.01

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2021-12-31	2022-06-30	2022-12-31	2023-06-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.95	0.87	0.12	0.07	0
Net income per share	-0.29	-0.11	-0.86	-0.64	0
Operating cash flow per share	-0.17	-0.1	-0.88	-0.63	0
Free cash flow per share	-0.19	-0.11	-0.89	-0.63	0
Cash per share	1.83	1.69	1.39	0.81	0
Book value per share	2.6	2.53	1.76	1.21	0
Tangible book value per share	-0.2	-0.17	-0.88	-1.35	0
Share holders equity per share	2.6	2.53	1.76	1.21	0
Interest debt per share	1.85	1.75	2.27	2.24	0
Market cap	188.16M	113.58M	123.2M	61.46M	0
Enterprise value	191.71M	118.16M	142.38M	90.2M	27.13M
P/E ratio	-8.77	-14.35	-1.95	-1.3	0
Price to sales ratio	10.86	7.08	54.64	45.26	0
POCF ratio	-59.6	-59.12	-7.54	-5.24	0
PFCF ratio	-53.73	-54.74	-7.49	-5.24	0
P/B Ratio	3.96	2.43	3.79	2.73	0
PTB ratio	3.96	2.43	3.79	2.73	0
EV to sales	11.06	7.36	63.14	66.42	31.22
Enterprise value over EBITDA	-35.97	-23.18	-9.2	-5.19	-2.41
EV to operating cash flow	-60.73	-61.51	-8.72	-7.69	-3.38
EV to free cash flow	-54.74	-56.94	-8.65	-7.69	-3.38
Earnings yield	-0.03	-0.02	-0.13	-0.19	0
Free cash flow yield	-0.02	-0.02	-0.13	-0.19	0
Debt to equity	0.7	0.68	1.27	1.8	1.86
Debt to assets	0.33	0.31	0.45	0.51	0.52
Net debt to EBITDA	-0.67	-0.9	-1.24	-1.65	-2.41
Current ratio	2.64	2.17	2.29	1.49	1.62
Interest coverage	-10.84	-10.24	-24.27	-18.27	-9.43
Income quality	0.59	0.97	1.03	0.99	0.72
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.3	0.23	1.25	2.63	0
Research and developement to revenue	0.97	1.03	5.99	10.62	12.45
Intangibles to total assets	0.5	0.49	0.53	0.59	0
Capex to operating cash flow	0.11	0.08	0.01	0	0
Capex to revenue	-0.02	-0.01	-0.05	0	0
Capex to depreciation	-0.2	-0.09	-0.07	0	0
Stock based compensation to revenue	0.06	0.07	0.86	1.15	0
Graham number	4.14	2.47	5.82	4.16	0
ROIC	-0.06	-0.03	-0.19	-0.24	-0.14
Return on tangible assets	-0.11	-0.04	-0.37	-0.36	-0.14
Graham Net	-0.8	-0.88	-1.48	-1.86	0
Working capital	27.44M	24.74M	20.93M	9.17M	11.68M
Tangible asset value	-3.59M	-3.16M	-16.24M	-25.08M	22.98M
Net current asset value	-9.78M	-9.54M	-21.92M	-30.15M	-28.6M
Invested capital	0.7	0.68	1.27	1.8	1.86
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	39.79	60.18	324.4	725.1	101.7
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	2.26	1.5	0.28	0.12	0.88
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.11	-0.04	-0.48	-0.53	-0.49
Capex per share	-0.02	-0.01	-0.01	0	0

OSE.PA Frequently Asked Questions

What is OSE Immunotherapeutics SA stock symbol ?

OSE Immunotherapeutics SA is a FR stock and trading under the symbol OSE.PA

What is OSE Immunotherapeutics SA stock quote today ?

OSE Immunotherapeutics SA stock price is $4.625 today.

Is OSE Immunotherapeutics SA stock public?

Yes, OSE Immunotherapeutics SA is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 120.72K
Market Capitalization 102.24M
Employee 62
CEO Dr. Nicolas Poirier Ph.D.
Headquarters Nantes,FR
IPO Date 2015-03-30
Website https://www.ose-immuno.com

OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of non-small cell lung cancer, as well as in Phase II clinical trial to pancreatic and ovarian cancer; CoVepiT, a prophylactic vaccine against the SARS-CoV-2 virus; BI 765063, which is in Phase I clinical trial to treat solid tumors; and BiCKI, a novel bispecific checkpoint inhibitor platform, targeting PD-1 and innovative targets to fight primary and secondary resistance mechanisms developed by cancers. The company's products also comprise OSE-127, a humanized monoclonal antibody that is in Phase II clinical trial for the treatment of ulcerative colitis, as well as Sjögren's Syndrome; FR104, which is in Phase I clinical trial for the treatment of rheumatoid arthritis; and OSE-230, an agonist antibody against ChemR23 to resolve chronic inflammation. OSE Immunotherapeutics SA has collaborations and partnerships with GERCOR, Boehringer Ingelheim, Servier, and Chong Kun Dang Pharmaceutical Corporation. The company was formerly known as OSE Pharma SA and changed its name to OSE Immunotherapeutics SA in May 2016. OSE Immunotherapeutics SA is headquartered in Nantes, France.